Deal Structure Guide · Medical Equipment Supplier

How to Structure a Medical Equipment Supplier Acquisition

From SBA 7(a) loans to earnouts and equity rollovers — a practical guide to deal structures for DMEPOS and durable medical equipment businesses in the $1M–$5M revenue range.

Acquiring or selling a medical equipment supplier involves deal structures shaped by the industry's unique mix of recurring rental revenue, Medicare/Medicaid reimbursement exposure, regulatory accreditation requirements, and supplier contract transferability. Unlike many lower middle market businesses, DMEPOS and DME acquisitions carry post-close regulatory risk — including reimbursement audits, accreditation continuity, and payer contract approvals — that meaningfully influences how purchase price is allocated and how risk is shared between buyer and seller. The most common structures in this space combine SBA 7(a) debt financing with seller notes or earnouts to bridge valuation gaps created by reimbursement uncertainty, while equity rollovers are increasingly used to retain seller involvement through regulatory transitions. Understanding which structure best fits your transaction depends on the quality of recurring revenue, the cleanliness of billing compliance history, the transferability of key supplier agreements, and the degree of owner dependency in the business.

Find Medical Equipment Supplier Businesses For Sale

SBA 7(a) Loan with Seller Note

The most common structure for lower middle market DME and DMEPOS acquisitions. The buyer funds the majority of the purchase price through an SBA 7(a) loan — typically covering 70–80% of the deal — with a 10–20% buyer equity injection and a seller note of 5–10% to bridge any valuation gap. The seller note is often subordinated to the SBA loan and structured as a standby note during the initial loan period. This structure is particularly well-suited for Medicare-accredited DME businesses with clean billing histories and diversified payer mixes.

SBA loan: 70–80% | Buyer equity: 10–20% | Seller note: 5–10%

Pros

  • Maximizes buyer leverage with favorable SBA loan terms including 10-year amortization and competitive interest rates
  • Aligns seller and buyer incentives through the subordinated seller note, motivating seller to support a clean transition
  • Accessible to entrepreneurial buyers and search fund operators without large equity pools

Cons

  • SBA lender underwriting scrutiny on Medicare/Medicaid revenue concentration and reimbursement risk can slow approval timelines
  • Seller note standby provisions restrict seller cash flow for 12–24 months post-close, which some sellers resist
  • Full goodwill and intangible asset valuation must be supportable to SBA standards, limiting aggressive pricing on owner-dependent businesses

Best for: Owner-operated DMEPOS businesses with $300K–$700K EBITDA, clean Medicare billing compliance, active accreditation, and diversified referral relationships — particularly where the seller is motivated by a clean exit and willing to hold a small note to support transition.

Asset Purchase with Earnout

The buyer acquires specified business assets — including inventory, equipment, supplier contracts, customer lists, and accreditations — rather than the legal entity. A portion of the purchase price is deferred as an earnout tied to post-close performance metrics such as retention of key supplier distribution agreements, Medicare/Medicaid reimbursement approval continuity, or recurring rental revenue thresholds over 12–24 months. This structure is common when there is meaningful uncertainty around regulatory continuity or the transferability of exclusive distribution agreements.

Cash at close: 75–85% | Earnout: 15–25% over 12–24 months

Pros

  • Limits buyer exposure to unknown pre-close billing compliance liabilities and historical Medicare audit risk retained by the selling entity
  • Earnout mechanics directly tie seller payout to the successful transfer of value drivers — supplier contracts, reimbursement approvals, and referral relationships
  • Asset step-up provides buyer with improved depreciation and amortization tax benefits post-close

Cons

  • Earnout disputes are common if performance metrics are not precisely defined — reimbursement rate changes by CMS can create ambiguity around revenue shortfalls
  • Asset purchase may require re-enrollment with Medicare/Medicaid under the buyer's provider numbers, creating a revenue gap during transition
  • Sellers may resist earnouts if they perceive post-close performance as outside their control due to payer or regulatory changes

Best for: Transactions where the business has meaningful Medicare/Medicaid revenue but carries some billing compliance history concerns, pending supplier contract renewals, or where the seller holds key physician or hospital referral relationships that require active transition support.

Equity Rollover with Partial Seller Retain

The seller retains a minority equity stake — typically 10–20% — in the acquired entity alongside a private equity buyer or strategic acquirer. The seller receives a majority cash payout at close while remaining an equity participant in the business going forward. This structure is most common in platform acquisitions or roll-up strategies where the seller's ongoing involvement is critical to regulatory continuity, physician referral relationship retention, or supplier agreement management during a defined transition period.

Cash at close: 80–90% | Equity rollover: 10–20%

Pros

  • Retains seller engagement and institutional knowledge through regulatory and accreditation transitions that can take 12–24 months to stabilize
  • Provides seller with upside participation in future value creation, often resulting in a higher total economic outcome than an outright sale
  • Demonstrates seller confidence in the business to buyers and lenders, reducing perceived post-close risk

Cons

  • Seller loses operational control while retaining financial exposure, which can create tension if the new owner changes strategy or pricing
  • Equity rollover terms require careful legal structuring — drag-along rights, put/call provisions, and minority protections add complexity and legal cost
  • Not well-suited for retiring sellers who want a clean break or those with estate planning constraints requiring full liquidity at close

Best for: Medical equipment suppliers being acquired by private equity-backed healthcare platforms or strategic regional distributors executing roll-up strategies, particularly where the seller's physician relationships, DMEPOS accreditation knowledge, or exclusive supplier agreements are central to near-term business continuity.

Sample Deal Structures

SBA-Financed Acquisition of a DMEPOS Business with Clean Billing History

$2,100,000

SBA 7(a) loan: $1,470,000 (70%) | Buyer equity injection: $420,000 (20%) | Seller note: $210,000 (10%)

SBA loan structured over 10 years at prevailing SBA rates; seller note on 24-month standby per SBA requirements, then amortized over 3 years at 6% interest. Business generates $350,000 EBITDA on $2.1M revenue, implying a 6x multiple reflecting strong recurring rental revenue (60% of total), active DMEPOS accreditation, and no open Medicare audit exposure. Seller note subordinated to SBA lender; seller provides 12-month transition support and non-solicitation covering physician and hospital referral sources.

Asset Purchase with Earnout — Supplier Contract Transferability Risk

$1,750,000 (up to $2,050,000 with earnout)

Cash at close: $1,487,500 (85% of base price) | Earnout: Up to $300,000 over 24 months tied to retention of two exclusive distribution agreements and Medicare revenue exceeding $850,000 annually post-close

Buyer acquires all tangible assets, customer lists, and assignable contracts; excludes entity-level liabilities. Earnout measured at 12 and 24 months post-close; each milestone pays $150,000 upon achieving defined revenue and contract thresholds. Seller re-enrolls Medicare provider number under buyer's new entity within 90 days of close with cooperation obligations. Seller funded primarily through buyer equity and conventional bank debt given asset purchase structure outside SBA eligibility due to real estate exclusion.

Equity Rollover — PE Platform Add-On Acquisition

$4,500,000

Cash at close to seller: $3,825,000 (85%) | Equity rollover at close: $675,000 equivalent to 15% minority stake in recapitalized entity

Private equity-backed regional DME platform acquires 85% of seller's DMEPOS business; seller retains 15% equity stake with standard minority protections, drag-along rights, and a put option at a defined EBITDA multiple exercisable after 36 months. Seller remains as non-executive advisor for 24 months to manage physician referral transitions and supplier relationship continuity. Platform financing includes senior debt at 3x EBITDA; seller's rollover equity valued at same entry multiple as PE platform acquisition. Total enterprise value of $4.5M reflects 5.5x EBITDA on $820,000 adjusted EBITDA with premium for exclusive regional distribution rights.

Negotiation Tips for Medical Equipment Supplier Deals

  • 1Segment recurring rental and service contract revenue from one-time equipment sales in your financial presentation — buyers will pay a meaningfully higher multiple for businesses where 50%+ of revenue is recurring, so clearly documenting this split before negotiations begin strengthens your pricing position.
  • 2Address Medicare and Medicaid reimbursement risk directly in deal structure by proposing earnout metrics tied to CMS revenue thresholds rather than total revenue — this allocates post-close reimbursement rate risk fairly between buyer and seller and reduces the likelihood of earnout disputes tied to factors outside the seller's control.
  • 3Confirm transferability of all supplier and distribution agreements before entering exclusivity — if key agreements require consent to assign or include change-of-control provisions, negotiate those consents in parallel with purchase agreement drafting to avoid closing delays or last-minute price concessions.
  • 4Use the seller note strategically to close valuation gaps created by DMEPOS accreditation uncertainty or pending Medicare re-enrollment timelines — a 5–10% seller note signals seller confidence in the business and satisfies SBA lenders who require skin-in-the-game from sellers in healthcare service transactions.
  • 5Build a detailed inventory aging report and agree on an inventory valuation methodology before signing the letter of intent — medical device inventory obsolescence is a common source of purchase price adjustment disputes at closing, and aligning on aging thresholds and write-down policies upfront protects both parties.
  • 6Negotiate a defined transition services period with specific seller obligations — covering physician referral introductions, supplier contact handoffs, and Medicare billing system training — as a contractual closing condition rather than a post-close best-efforts commitment, ensuring the seller's transition support is enforceable and tied to any deferred consideration payments.

Find Medical Equipment Supplier Businesses For Sale

Pre-screened targets ready for your deal structure — free to join.

Get Deal Flow

Frequently Asked Questions

What is the most common deal structure for acquiring a DMEPOS or DME business?

The most common structure is an SBA 7(a) loan covering 70–80% of the purchase price, combined with a 10–20% buyer equity injection and a 5–10% seller note. This structure works well for Medicare-accredited medical equipment suppliers with clean billing histories and $300K–$700K in EBITDA. SBA financing is attractive because it offers 10-year amortization at competitive rates, making debt service manageable relative to the business's cash flow — particularly important in DME businesses where reimbursement rate variability can affect EBITDA year over year.

How does Medicare and Medicaid revenue affect deal structure in a medical equipment supplier acquisition?

Medicare and Medicaid revenue is both a value driver and a source of deal structure complexity. Buyers pay premium multiples for businesses with stable, diversified Medicare reimbursement — but that same revenue creates post-close risk around CMS billing audits, reimbursement rate changes, and re-enrollment timelines when the business transfers. As a result, buyers often propose earnout provisions tied to maintaining Medicare revenue thresholds post-close, or structure asset purchases that exclude pre-close billing liabilities. Sellers should conduct an internal billing compliance review before going to market to reduce buyer concern and minimize the risk of earnout or escrow provisions.

Can an earnout be structured around supplier contract retention in a DME acquisition?

Yes — earnouts tied to supplier and distribution agreement retention are common in DMEPOS acquisitions where the business holds exclusive or preferred distribution rights with nationally recognized medical brands. The earnout is typically paid in tranches at 12 and 24 months post-close, contingent on confirming that key contracts have been successfully assigned to the buyer and remain in good standing. Buyers should ensure the earnout metrics are objectively measurable and not subject to third-party consent risk outside the seller's control, while sellers should negotiate for earnout protections if a supplier declines to transfer a contract despite good-faith efforts.

What role does equity rollover play in medical equipment supplier transactions?

Equity rollovers — where the seller retains a 10–20% minority stake post-close — are most common when a private equity-backed platform or strategic acquirer is buying the business as part of a roll-up strategy. The rollover serves two purposes: it retains the seller's institutional knowledge and referral relationships during the regulatory transition period, and it signals seller confidence in the business's future performance. For sellers, the rollover provides upside participation if the acquirer grows the platform and exits at a higher multiple. It is less suitable for retiring owners seeking full liquidity at close.

How are inventory and equipment valued in a medical equipment supplier deal?

Inventory and capital equipment are typically valued through a combination of cost-basis aging analysis and fair market valuation, often conducted by a third-party appraiser as part of due diligence. Buyers focus heavily on inventory obsolescence risk — particularly for medical devices with short technology cycles — and will negotiate purchase price adjustments or closing-date inventory verification provisions. A common structure includes a net working capital peg that defines an agreed inventory value at close, with dollar-for-dollar adjustments if the final count falls short. Sellers should prepare a detailed inventory aging report with write-down analysis before entering exclusivity to avoid last-minute closing surprises.

Is seller financing common in medical equipment supplier acquisitions, and what are typical terms?

Seller financing in the form of a subordinated seller note is common, particularly in SBA-structured transactions where the lender requires the seller to hold 5–10% of the purchase price as a standby note. Typical terms include a 24-month standby period during which no payments are made, followed by 3–5 year amortization at 5–7% interest. Seller notes serve as a confidence signal to SBA lenders and help bridge valuation gaps, especially in businesses where a portion of value is tied to relationships or accreditations that take time to confirm post-close. Sellers should expect SBA lenders to require the note to be fully subordinated to the senior loan throughout its term.

More Medical Equipment Supplier Guides

More Deal Structure Guides

Start Finding Medical Equipment Supplier Deals Today — Free to Join

Find the right target, structure the deal, and close with confidence.

Create your free account

No credit card required